Skip to main content

New risk factor for leukoencephalopathy Progressive multifocal (PML) associated with Tysabri (natalizumab)


The Food and Drug Administration (FDA) and inform the public that have been identified to test positive for antibodies against JC (JCV) as a risk factor for HIV leukoencephalopathy progressive multifocal (PML). PML is an inflammation of the brain are rare but serious associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis (MS) or Crohn's disease.
It should be that the risks and benefits of continuing treatment with Tysabri be carefully considered in patients who are found to be anti-JCV antibodies of the positive and you have one or more of the other risk factors known to the PML. Patients who suffer from all the three known risk factors have estimated the risk of PML of 11/1 for users, 000. Risk factors are:The presence of antibodies against JCV.Longer duration of treatment Tysabri, especially after 2 years.Before treatment with immunosuppressive drugs (for example, mitoxantrone, azathioprine, methotrexate, cyclophosphamide, or inhibition mofetil).
Has been revised drug label for Tysabri to reflect this updated information including the schedule of estimating the rate of PML stratified by three known risk factors.
Can determine the status of the patient's antibodies to anti-JCV antibody detection using the anti-JCV test that has been verified analytically and clinically, and ordered by a physician. JCV was cleared applied body ELISA test by the FDA on January 20, 2012.Test positive for anti-JCV antibodies means that a person is exposed to JCV in the past
Labels:

Comments

  1. Anonymous16 April 2012 at 14:27

    This is going to be a conclusive test for MS patients opting for Tysabri as treatment. In case the patients is tested positive certain measures should be taken:
    -closer monitoring for any signs of PML;
    -decrease the time between MRI scans.
    The doctors treating patients more susceptible to PML should be prepared to offer progressive multifocal leukoencephalopathy treatments as fast as possible.

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

New and Generic Drug Approvals

September 5, 2012 Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type Amlodipine Besylate; Benazepril Hydrochloride amlodipine besylate; benazepril hydrochloride Capsule; Oral Aurobindo Pharma Ltd Approval Declomycin demeclocycline hydrochloride Tablet; Oral Corepharma Labeling Revision Trilipix choline fenofibrate Capsule, Delayed Release; Oral Abbott Labs Labeling Revision Trilipix choline fenofibrate Capsule, Delayed Release; Oral Abbott Labs Manufacturing Change or Addition Ziprasidone Hydrochloride ziprasidone hydrochloride Capsule; Oral Wockhardt Ltd Approval
1 comment
Read more